Routes for Drug Delivery: Sustained-Release Devices

Area of Science:

• Ophthalmology
• Biomaterials Science
• Drug Delivery Systems

Background:

• Several sustained-release drug delivery technologies are available for retinal diseases, including nonbiodegradable and biodegradable implants, micro/nanoparticles, liposomes, and encapsulated cell technology (ECT).
• Current FDA-approved sustained-release devices for retinal conditions include ganciclovir and fluocinolone acetonide implants (nonbiodegradable, surgical placement) and a dexamethasone implant (biodegradable, injectable).

Purpose of the Study:

• To review existing and emerging sustained-release drug delivery technologies for retinal diseases.
• To highlight the advantages and limitations of different delivery systems.
• To discuss the potential of novel technologies for future therapeutic applications.

Main Methods:

• Literature review of sustained-release drug delivery systems for ophthalmic applications.
• Analysis of currently approved sustained-release implants by the FDA.
• Examination of emerging technologies such as micro/nanoparticles, liposomes, and ECT.

Main Results:

• Nonbiodegradable implants require surgery, while the biodegradable dexamethasone implant offers easier administration.
• Encapsulated cell technology (ECT) is in clinical trials, using modified cells for in-situ drug production.
• Microparticle, nanoparticle, and liposome technologies show promise for flexible, prolonged drug release and combination therapies.

Conclusions:

• Biodegradable implants and emerging technologies like micro/nanoparticles, liposomes, and ECT represent significant advancements in sustained drug delivery for retinal diseases.
• These novel approaches offer greater flexibility, potential for combination therapy, and improved patient compliance compared to traditional nonbiodegradable implants.
• Further development of these technologies is crucial for addressing unmet needs in managing chronic and complex retinal conditions.